Comparative Pharmacology
Head-to-head clinical analysis: XYLOCAINE 1 5 W DEXTROSE 7 5 versus XYLOCAINE 4 PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XYLOCAINE 1 5 W DEXTROSE 7 5 versus XYLOCAINE 4 PRESERVATIVE FREE.
XYLOCAINE 1.5% W/ DEXTROSE 7.5% vs XYLOCAINE 4% PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that blocks sodium channels, thereby inhibiting the propagation of action potentials in peripheral nerves, leading to local anesthesia.
Lidocaine stabilizes the neuronal membrane by inhibiting sodium ion influx through voltage-gated sodium channels, thereby blocking the initiation and propagation of action potentials, resulting in local anesthesia.
Spinal anesthesia: 1.5-2 mL (22.5-30 mg lidocaine) for lower extremity or perineal procedures; 2-3 mL (30-45 mg) for lower abdominal or urological procedures. Administered via lumbar puncture.
Maximum 4.5 mg/kg (not to exceed 300 mg) via subcutaneous infiltration, epidural, or nerve block; repeat dosing after 30 minutes if needed.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in adults with normal hepatic function; may be prolonged to 3–5 hours in patients with hepatic impairment or congestive heart failure.
Terminal elimination half-life: ~1.5–2 hours (adults). Prolonged in hepatic impairment, congestive heart failure, or neonates.
Renal excretion of metabolites (predominantly 4-hydroxy-2,6-xylidine and conjugates) accounts for >80% of elimination; less than 10% eliminated unchanged in urine. Biliary/fecal excretion of metabolites contributes <10%.
Renal: ~90% as metabolites (mostly 4-hydroxy-2,6-xylidine and conjugates); <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Local Anesthetic
Local Anesthetic